Exagen Inc stock (US30063K1051): Q1 revenue hits record $17.3M, up 12%

Exagen Inc, a molecular diagnostics firm targeting autoimmune diseases, posted record first-quarter revenue of $17.3 million, up 12% from the prior year, according to GuruFocus as of May 2026. The company also maintained its full-year 2026 revenue outlook at $70-73 million, signaling 5-10% growth, as noted in Investing.com as of May 2026. BTIG lowered its price target to $8 citing valuation.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Exagen Inc: core business model

Exagen Inc develops and markets molecular diagnostics for autoimmune diseases, including lupus and rheumatoid arthritis. Its flagship Avise tests aid in diagnosis and monitoring, helping physicians manage patient care more effectively. Headquartered in the US, the company focuses on tests that measure biomarkers for precise treatment decisions, as described on its website.

The business model centers on lab-developed tests reimbursed through US healthcare payers, with expansion into physician offices and international markets. Exagen's pharmacogenetic testing complements its core offerings, supporting personalized medicine in immunology.

Main revenue and product drivers for Exagen Inc

Revenue primarily stems from Avise Lupus and Avise CTD tests, which drove the Q1 2026 figure to $17.3 million, up 12% year-over-year per GuruFocus May 2026. The company reaffirmed 2026 guidance of $70-73 million, implying steady growth from diagnostic volume increases.

Key drivers include test adoption by rheumatologists and reimbursement contracts with major US insurers, bolstering accessibility for the 16 million Americans affected by autoimmune conditions.

Industry trends and competitive position

The diagnostics sector sees rising demand for precision medicine amid autoimmune prevalence, with US market growth projected at 7-9% annually through 2030 per sector reports. Exagen competes with larger players like Quest Diagnostics but differentiates via specialized immunology panels.

Why Exagen Inc matters for US investors

Listed on Nasdaq as XGN, Exagen offers US investors exposure to the $10+ billion autoimmune diagnostics market, tied to healthcare spending which comprises 18% of US GDP. Its focus on high-prevalence diseases like lupus aligns with demographic trends in an aging population.

Conclusion

Exagen Inc's Q1 revenue growth to $17.3 million underscores execution on its diagnostics platform, with steady 2026 guidance amid analyst scrutiny on valuation. The stock's volatility reflects biotech dynamics, offering insights into autoimmune testing demand. Investors track upcoming quarters for sustained momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.